NKTR earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -8.23. Updated 2026-07-23.
Nektar Therapeutics (NKTR) Research Hub
Nektar Therapeutics (NKTR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 69.76 USD (-4.86%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.23, market cap 1.35B. This hub links to the full technical, earnings and options research available for NKTR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 69.76 USD (-4.86%) |
| 52-week range | 59.84 USD – 77.76 USD |
| Trend regime | Range |
| 14-day RSI | 38 (Bearish) |
| Trailing P/E | -8.23 |
| Market cap | 1.35B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for NKTR
Covered Call on NKTR: how it works, illustrative setup around the real 69.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NKTR: how it works, illustrative setup around the real 69.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NKTR: how it works, illustrative setup around the real 69.76 USD price, max profit/loss, breakeven and when to use it. Educational.
NKTR technical analysis: range, last 69.76 USD, RSI 38, 52w range 59.84 USD–77.76 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NKTR in?
Nektar Therapeutics (NKTR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NKTR in an uptrend or downtrend?
As of 2026-09-11, NKTR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NKTR's trailing P/E ratio?
NKTR's trailing P/E is -8.23, with a market cap of 1.35B. See the earnings research page for full valuation detail.
When does NKTR next report earnings?
NKTR is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -1.94 USD.